AlphAIAlphAI — Financial news for AI agents
stocktwits.comSEP 112 min read$AXSM

AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’

Axsome Therapeutics (AXSM) shares rose 6% after Mizuho analyst cited strong August prescription data for Auvelity, its drug for Alzheimer's agitation. New prescriptions increased 32% from July. The analyst maintains an 'Outperform' rating with a $316 price target. Auvelity's Alzheimer's launch is key to the company's growth, with Q2 sales of $180.3M, up 51% YoY.

Original reporting
stocktwits.com
Published Sep 11, 2026, 7:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$AXSM
Bullish
high confidence
Mentioned
$AXSM
Relevance
7/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The early prescription surge signals a strong commercial start, reinforcing the analyst's outperform rating.

02

Market read

New launch data drives a notable intraday move, offering a short‑term trading opportunity.

03

What to watch

Potential reimbursement challenges and slower adoption in nursing homes.

Relevance 7/10Novelty 7/10Timing: Friday

Background

Axsome Therapeutics recently received FDA clearance for Auvelity in Alzheimer’s agitation and began sales in June.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Mizuho analyst reports 32% rise in new Auvelity prescriptions for Alzheimer’s, driving a 6% stock jump.

Expected impact

Potential upside of 10-15% over the next few weeks if prescription growth sustains.

Evidence & confidence

Analyst upgrade with $316 target and early adoption metrics indicate durable demand.

Market effects

Sector

Boosts outlook for biotech firms with new CNS indications.

Regional

Positive for US biotech sector investors.

Global

Limited to investors tracking Alzheimer’s therapeutics.

Counterpoint

What could challenge this read

Prescription growth may plateau; competition from antipsychotics could limit upside.

Key entities

  • Company
    Axsome Therapeutics

    Biotech developer of Auvelity.

  • Analyst
    Mizuho Securities

    Provided upgrade and price target.

Read at source← All news

Related articles

SEP 12
$AXSMMedAI 8/10

Should First Patient Dosed Require Action From Axsome Therapeutics Stock Investors?

Axsome Therapeutics (AXSM) dosed the first patient in a Phase 3 trial (SUMMIT) for AXS-05 in smoking cessation. The trial compares AXS-05 to bupropion and placebo, with abstinence at week 12 as the primary endpoint. Success could expand AXS-05's use and leverage its patent estate until 2043. Analysts project $2.5B revenue and $908.3M earnings by 2029, but risks include cash burn and trial execution.

simplywall.st3 min
SEP 6
$AXSMMedAI 8/10

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following AXS-05 Phase 3 Smoking Trial Launch

Axsome Therapeutics (AXSM) has initiated a Phase 3 trial for AXS-05 in smoking cessation, aiming to expand its use beyond existing approvals. The trial's success could enhance the company's long-term outlook, though near-term focus remains on commercializing Auvelity, Sunosi, and SYMBRAVO. Analysts project varying revenue and earnings forecasts for 2029, with some seeing significant upside.

simplywall.st3 min
AUG 31
$AXSMMedAI 8/10

Axsome doses first patient in phase 3 smoking cessation trial

Axsome Therapeutics (AXSM) dosed the first patient in its Phase 3 SUMMIT trial for AXS-05 as a smoking cessation treatment. The study will assess efficacy and safety over 12 weeks. AXS-05 is approved for other uses but not yet for smoking cessation. The company holds patents for the drug until at least 2043. Smoking affects 34 million adults in the U.S., costing over $300 billion annually.

investing.com2 min